Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
Overview of probable resistance mechanisms in EGFR-TKI afatinib.... | Download Scientific Diagram
Figure 2 from Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. | Semantic Scholar
The mechanism of acquired resistance to epidermal growth factor... | Download Scientific Diagram
![Mechanisms of acquired resistance to osimertinib [32-36]. EGFR,... | Download Scientific Diagram](https://www.researchgate.net/publication/328978288/figure/fig2/AS:693427310178304@1542337362022/Mechanisms-of-acquired-resistance-to-osimertinib-32-36-EGFR-epidermal-growth-factor.png "Mechanisms of acquired resistance to osimertinib [32-36]. EGFR,... | Download Scientific Diagram")
Mechanisms of acquired resistance to osimertinib [32-36]. EGFR,... | Download Scientific Diagram
New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
Resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer and strategies to overcome it | Australian Medical Student Journal
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer | European Respiratory Society
IJMS | Free Full-Text | Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy | HTML
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
11 Terapias dirigidas Cáncer de Pulmón
Does c-Met remain a rational target for therapy in patients with EGFR TKI- resistant non-small cell lung cancer? - Cancer Treatment Reviews
Mechanisms of osimertinib resistance and emerging treatment options - Lung Cancer
Diagnostics of EGFR-mutant disease: biomarkers with significant clinical implications - memoinOncology
Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer
PDF) MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients - Annals of Oncology
Cells | Free Full-Text | Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy | HTML
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics | PNAS
HCC827 GR cells are resistant to gefitinib in vitro and show MET... | Download Scientific Diagram
